GRACE THERAPEUTICS INC (GRCE) Fundamental Analysis & Valuation

NASDAQ:GRCE • US00439U1043

3.98 USD
+0.05 (+1.27%)
Last: Mar 10, 2026, 02:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GRCE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall GRCE gets a fundamental rating of 3 out of 10. We evaluated GRCE against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for GRCE as it has an excellent financial health rating, but there are worries on the profitability. GRCE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. GRCE Profitability Analysis

1.1 Basic Checks

  • In the past year GRCE has reported negative net income.
  • GRCE had a negative operating cash flow in the past year.
  • In the past 5 years GRCE always reported negative net income.
  • GRCE had a negative operating cash flow in each of the past 5 years.
GRCE Yearly Net Income VS EBIT VS OCF VS FCFGRCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • GRCE's Return On Assets of -8.73% is fine compared to the rest of the industry. GRCE outperforms 70.47% of its industry peers.
  • GRCE has a better Return On Equity (-9.21%) than 76.17% of its industry peers.
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROIC N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
GRCE Yearly ROA, ROE, ROICGRCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • GRCE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRCE Yearly Profit, Operating, Gross MarginsGRCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. GRCE Health Analysis

2.1 Basic Checks

  • GRCE has more shares outstanding than it did 1 year ago.
  • GRCE has more shares outstanding than it did 5 years ago.
  • GRCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GRCE Yearly Shares OutstandingGRCE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
GRCE Yearly Total Debt VS Total AssetsGRCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • GRCE has an Altman-Z score of 5.27. This indicates that GRCE is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of GRCE (5.27) is better than 76.17% of its industry peers.
  • GRCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.27
ROIC/WACCN/A
WACCN/A
GRCE Yearly LT Debt VS Equity VS FCFGRCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

  • GRCE has a Current Ratio of 14.96. This indicates that GRCE is financially healthy and has no problem in meeting its short term obligations.
  • GRCE's Current ratio of 14.96 is amongst the best of the industry. GRCE outperforms 85.49% of its industry peers.
  • A Quick Ratio of 14.96 indicates that GRCE has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 14.96, GRCE belongs to the best of the industry, outperforming 86.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 14.96
Quick Ratio 14.96
GRCE Yearly Current Assets VS Current LiabilitesGRCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. GRCE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 70.21% over the past year.
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 31.44% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y6.98%
EPS Next 5Y31.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRCE Yearly Revenue VS EstimatesGRCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M
GRCE Yearly EPS VS EstimatesGRCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. GRCE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GRCE. In the last year negative earnings were reported.
  • Also next year GRCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRCE Price Earnings VS Forward Price EarningsGRCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRCE Per share dataGRCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.59%
EPS Next 3Y6.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GRCE Dividend Analysis

5.1 Amount

  • GRCE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GRCE Fundamentals: All Metrics, Ratios and Statistics

GRACE THERAPEUTICS INC

NASDAQ:GRCE (3/10/2026, 2:07:27 PM)

3.98

+0.05 (+1.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-12
Earnings (Next)06-26
Inst Owners23.67%
Inst Owner ChangeN/A
Ins Owners3.21%
Ins Owner ChangeN/A
Market Cap61.57M
Revenue(TTM)N/A
Net Income(TTM)-5.98M
Analysts82.5
Price Target11.73 (194.72%)
Short Float %0.62%
Short Ratio0.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)59.59%
Min EPS beat(2)50.98%
Max EPS beat(2)68.2%
EPS beat(4)4
Avg EPS beat(4)64.31%
Min EPS beat(4)6.42%
Max EPS beat(4)131.63%
EPS beat(8)7
Avg EPS beat(8)46.23%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.43%
PT rev (3m)-1.43%
EPS NQ rev (1m)5.71%
EPS NQ rev (3m)5.71%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 3.94
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS4.19
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.73%
ROE -9.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.27%
ROA(5y)-44.34%
ROE(3y)-30.76%
ROE(5y)-64.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.96
Quick Ratio 14.96
Altman-Z 5.27
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y-43.32%
EPS Next 2Y-9.59%
EPS Next 3Y6.98%
EPS Next 5Y31.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.02%
EBIT Next 3Y1.32%
EBIT Next 5Y23.12%
FCF growth 1Y35.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.61%
OCF growth 3YN/A
OCF growth 5YN/A

GRACE THERAPEUTICS INC / GRCE FAQ

What is the fundamental rating for GRCE stock?

ChartMill assigns a fundamental rating of 3 / 10 to GRCE.


What is the valuation status of GRACE THERAPEUTICS INC (GRCE) stock?

ChartMill assigns a valuation rating of 0 / 10 to GRACE THERAPEUTICS INC (GRCE). This can be considered as Overvalued.


How profitable is GRACE THERAPEUTICS INC (GRCE) stock?

GRACE THERAPEUTICS INC (GRCE) has a profitability rating of 1 / 10.


How financially healthy is GRACE THERAPEUTICS INC?

The financial health rating of GRACE THERAPEUTICS INC (GRCE) is 8 / 10.